Acacia Technologies

Acacia Research Corporation (Nasdaq: ACTG) is a publicly traded investment firm that acquires and operates businesses across the life sciences, technology, and energy sectors. Historically recognized for its leadership in patent licensing and enforcement through its Acacia Technologies division, the company has transitioned into a strategic capital allocator with a robust portfolio of healthcare assets. In 2020, Acacia significantly expanded its life science footprint by acquiring a £224 million portfolio of 19 public and private companies, including stakes in Oxford Nanopore Technologies and Viamet Pharmaceuticals. The company leverages its deep expertise in intellectual property and complex financial structuring to identify and monetize undervalued innovations in the biotechnology and medical technology fields. Note: This company is distinct from Acacia Pharma, a supportive care biotech acquired by Eagle Pharmaceuticals in 2022.